ArticleAdvanced healthcare materials2026
Biofabrication of Endothelialized, Intrinsically Vascularized 3D-Printed Recombinant Spider Silk Scaffolds.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Tissue engineering aims to create functional tissues for regenerative medicine, where scaffold design and vascular integration remain key challenges. Therefore, the capability to promote vascularization, long-term stability and biocompatibility are important requirements to a scaffold material. One goal is to optimize the cell-to-scaffold material interaction to support vascularization and de novo tissue formation. This study evaluates 3D-printed and non-printed recombinant spider silk protein eADF4(C16)-RGD hydrogels in a rat arteriovenous (AV) loop model. The hydrogels were implanted subcutaneously using polytetrafluorethylene (PTFE) chambers, where the lower half contained an acellular 3D-printed spider silk hydrogel, while the upper half either contained a manually extruded eADF4(C16)-RGD hydrogel without cells (group A) or with T17b endothelial progenitor (EPCs) cells embedded (group B). Constructs were explanted after 2, 4, and 12 weeks. The 3D-printed eADF4(C16)-RGD scaffolds showed good biocompatibility and vascularization. Interestingly, the presence of T17b cells resulted in an increased biodegradation, with the 12 week constructs nearly completely dissolved. The cell-laden constructs showed a significantly increased vascular density per construct area after 4 weeks compared to the cell-free constructs. This study demonstrates that both the scaffold ultrastructure and the integration of T17b cells are effective strategies to enhance the functionality of biomaterials for tissue engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.